BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6191064)

  • 1. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
    Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Excretion of urinary hydroxyproline in urinary tract diseases].
    Guarino A; Comar OB; Taccone W; Cicalese V
    Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K; Aoyagi K
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyproline as a marker for following patients with metastatic prostate cancer.
    O'Brien WM; Lynch JH
    J Urol; 1988 Jan; 139(1):66-8. PubMed ID: 3121868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
    Mooppan MM; Wax SH; Kim H; Wang JC; Tobin MS
    J Urol; 1980 May; 123(5):694-6. PubMed ID: 7420557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
    Matsushita Y; Hasegawa K; Sugimura R; Otomo S; Morii H
    Endocrinol Jpn; 1974 Apr; 21(2):109-13. PubMed ID: 4408206
    [No Abstract]   [Full Text] [Related]  

  • 10. Study of hydroxyproline excretion in patients with prostatic cancer.
    Romics I; Budavári I; Kisbenedek L; Balogh F
    Int Urol Nephrol; 1981; 13(3):275-8. PubMed ID: 7327902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
    de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
    Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
    [No Abstract]   [Full Text] [Related]  

  • 12. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
    Nemoto S; Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
    [No Abstract]   [Full Text] [Related]  

  • 13. Urinary hydroxyproline excretion in patients with cancer.
    Guzzo CE; Pachas WN; Pinals RS; Krant MJ
    Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
    [No Abstract]   [Full Text] [Related]  

  • 14. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
    Hopkins SC; Nissenkorn I; Palmieri GM; Ikard M; Moinuddin M; Soloway MS
    J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
    Bishop MC; Fellows GJ
    Br J Urol; 1977; 49(7):711-6. PubMed ID: 597712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
    Ikeda I; Miura T; Kondo I
    Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary hydroxyproline levels in patients with prostatic carcinoma.
    Erol D; Adalar N; Güvençli S; Simşek F
    Int Urol Nephrol; 1983; 15(3):267-70. PubMed ID: 6654633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases.
    Heller W; Harzmann R; Bichler KH; Schmidt K
    Curr Probl Clin Biochem; 1979; (9):249-56. PubMed ID: 446076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyproline excretion in malignant neoplastic disease.
    Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
    Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
    [No Abstract]   [Full Text] [Related]  

  • 20. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
    Gasser AB; Jeannet C; Depierre D; Courvoisier B
    Schweiz Med Wochenschr; 1981 Feb; 111(8):246-51. PubMed ID: 7233140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.